333 related articles for article (PubMed ID: 30302873)
1. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
3.
Kuramochi H; Nakajima GO; Hayashi K; Araida T; Yamamoto M
Anticancer Res; 2019 Sep; 39(9):4729-4736. PubMed ID: 31519572
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.
Jing C; Jin YH; You Z; Qiong Q; Jun Z
Oncotarget; 2016 Aug; 7(34):55890-55899. PubMed ID: 27344184
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
[TBL] [Abstract][Full Text] [Related]
6. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Stahler A; Heinemann V; Giessen-Jung C; Crispin A; Schalhorn A; Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Quietzsch D; Held S; von Einem JC; Holch J; Neumann J; Kirchner T; Jung A; Modest DP
Int J Cancer; 2016 Feb; 138(3):739-46. PubMed ID: 26284333
[TBL] [Abstract][Full Text] [Related]
7. Amphiregulin Expression Is a Predictive Biomarker for
Stahler A; Stintzing S; Modest DP; Ricard I; Giessen-Jung C; Kapaun C; Ivanova B; Kaiser F; Fischer von Weikersthal L; Moosmann N; Schalhorn A; Stauch M; Kiani A; Held S; Decker T; Moehler M; Neumann J; Kirchner T; Jung A; Heinemann V
Clin Cancer Res; 2020 Dec; 26(24):6559-6567. PubMed ID: 32943459
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
9. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
10. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
12. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
13. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
[TBL] [Abstract][Full Text] [Related]
15. Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer.
Williams CJM; Elliott F; Sapanara N; Aghaei F; Zhang L; Muranyi A; Yan D; Bai I; Zhao Z; Shires M; Wood HM; Richman SD; Hemmings G; Hale M; Bottomley D; Galvin L; Cartlidge C; Dance S; Bacon CM; Mansfield L; Young-Zvandasara K; Sudan A; Lambert K; Bibby I; Coupland SE; Montazeri A; Kipling N; Hughes K; Cross SS; Dewdney A; Pheasey L; Leng C; Gochera T; Mangham DC; Saunders M; Pritchard M; Stott H; Mukherjee A; Ilyas M; Silverman R; Hyland G; Sculthorpe D; Thornton K; Gould I; O'Callaghan A; Brown N; Turnbull S; Shaw L; Seymour MT; West NP; Seligmann JF; Singh S; Shanmugam K; Quirke P
Clin Cancer Res; 2023 Oct; 29(20):4153-4165. PubMed ID: 37363997
[TBL] [Abstract][Full Text] [Related]
16. The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma.
da Costa AABA; Costa FD; Araújo DV; Camandaroba MPG; de Jesus VHF; Oliveira A; Alves ACF; Stecca C; Machado L; de Oliveira ACF; de Oliveira TB; Nicolau UR; de Lima VCC
Med Oncol; 2018 Nov; 36(1):8. PubMed ID: 30478503
[TBL] [Abstract][Full Text] [Related]
17. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Jacobs B; De Roock W; Piessevaux H; Van Oirbeek R; Biesmans B; De Schutter J; Fieuws S; Vandesompele J; Peeters M; Van Laethem JL; Humblet Y; Pénault-Llorca F; De Hertogh G; Laurent-Puig P; Van Cutsem E; Tejpar S
J Clin Oncol; 2009 Oct; 27(30):5068-74. PubMed ID: 19738126
[TBL] [Abstract][Full Text] [Related]
18. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.
Kuramochi H; Nakajima G; Kaneko Y; Nakamura A; Inoue Y; Yamamoto M; Hayashi K
BMC Cancer; 2012 Mar; 12():88. PubMed ID: 22409860
[TBL] [Abstract][Full Text] [Related]
19. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
20. Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
Magnes T; Melchardt T; Weiss L; Mittermair C; Neureiter D; Klieser E; Gampenrieder S; Moser G; Gaggl A; Greil R; Egle A
PLoS One; 2017; 12(7):e0180995. PubMed ID: 28686697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
